Manufacturers Come to Grips with Realities of Biomonitoring
Regulatory initiatives based upon biomonitoring
data have expanded greatly in recent years. For the manufacturing
sector, this poses both opportunities and risks.
Biomonitoring, according to the Centers for Disease
Control and Prevention (CDC), is the “direct measurement
of environmental chemicals in the human body, specifically
in blood, urine, serum, saliva or tissues.”
These environmental chemicals can be “present in air, water, soil, dust, food or other environmental media.” In the recent past, the U.S. government,
as well as various international regulatory bodies, have significantly increased standard-setting and related initiatives based on the presence of environmental chemicals found in bodily fluids. Given advances in the capability of analytical detection equipment, and the heightened awareness of and
sensitivity to the consequences of a “toxic trespass,” as certain non-government organizations (NGOs) characterize it, there is little wonder there has been a significant increase in the number of rulemaking, policy and litigation initiatives with a biomonitoring component.